


Weekly Wrap Up - 2022 Week 5

The rate of southern region COVID-19 hospitalizations is slowing down, while the northern region continues to accelerate. Staffing remains an issue throughout the healthcare continuum with employees requiring isolation or suffering from illnesses. Staffing challenges affect doctors' offices, skilled nursing facilities, public health departments, and hospitals alike. Vaccine manufacturers are testing Omicron-specific vaccines. The FDA expands approval for remdesivir use and restricts the use of other MAbs. The NHA made changes to our medical intelligence program and how data is collected from hospitals.



Risk Table Highlights: The risk table has not changed from week 4 to week 5. The NHA continues to recognize hospital staffing concerns. COVID-19 hospitalizations remain in warning status for the south as hospitalizations are high and continue to climb, albeit slower than in previous weeks. COVID-19 hospitalizations remain in watch status for the north; however, with the COVID-19 hospitalizations continuing to rise, readers should not be surprised if the trend continues for this indicator to be elevated to a warning in the coming weeks. While Omicron appears to be less virulent than other variants, the sheer volume of cases is stressing the hospitals combined with employee illness and required isolation days. PPE and vents experience no issues and have been stable since the introduction of this table. These risk table elements are being studied, and their removal from this table is anticipated in the coming weeks. Supplies remain in watch status based on influences by the global supply chain and logistics components. Hospitals are not reporting shortages with the one exception being blood products. Supplies of therapeutics, including MAbs and the Pfizer treatment (PAXLVID), are reported to remain in very short supply within the healthcare sector as the manufacturers have not been able to scale up production to meet demand at this point.

County	COVID-19 Hospitalization Status	Confirmed Hospitalization 7-Day Moving Average 1/12/2022	Confirmed Hospitalization 7-Day Moving Average 1/25/2022
Carson City	Increasing	25	43
Churchill	Increasing	6	8
Clark	Increasing	1318	1678
Douglas	Flat	6	5
Elko	Increasing	0	5
Humboldt	Flat	1	2
Lander	Flat	1	0
Lincoln	None	0	0
Lyon	Flat	1	1
Mineral	Flat	0	3
Nye	Flat	7	9
Pershing	None	0	0
Washoe	Increasing	93	214
White Pine	Flat	2	3

The FDA makes several changes to COVID-19 Emergency Use Authorizations (EUAs). (1) FDA updated the Emergency Use Authorization (EUA) fact sheets for two COVID-19 monoclonal antibody treatments: Lilly's bamlanivimab plus etesevimab and Regeneron's casirivimab plus imdevimab (REGEN-COV). FDA now says these two treatments are not currently authorized for use anywhere in the U.S. due to the prevalence of Omicron. (2) The FDA updated the fact sheet for remdesivir, allowing this treatment for certain non-hospitalized patients. Previously, hospitalization was a requirement for specific patient types.

A new subvariant of Omicron (BA.2.) has been detected in several U.S. states and 40 additional countries. Scientists and public health agencies will watch and study the new subvariant separately from Omicron to see if it behaves differently. The World Health Organization maintains that BA.2 is **not** a "variant of concern," meaning there is no current evidence to suggest this new subvariant will worsen COVID-19 transmission, illness severity, or efficacy of vaccines and public health efforts like masking and social distancing.

Reminders: (1) Hospitals are reminded that the new NHA survey goes into effect tomorrow Thursday, January 27, 2022. This survey is compliant with the new HHS/CMS requirements. The NHA may temporarily restrict access to the COVID-19 portal to ensure the data linkages work correctly following the system switchover. If you have difficulty accessing the portal, please rest assured that the NHA will have it operational quickly following any identified issues. Please email covid@nvha.net if you experience any portal problems or concerns about the data stream. (2) Thursday, January 27, 2022, is the first day that the CDC vaccine mandate will be enforced.